J&J’s covid vaccine rollout resumes in Europe, with safety warning after EMA’s green signal
Johnson & Johnson announced Tuesday that it will resume the distribution of its COVID-19 vaccine in Europe after the European Union’s (EU) medical regulator approved of the same but with a safety warning, per Reuters.
The European Medicines Agency (EMA) recommended adding a warning about rare blood clots with low blood platelet count to the vaccine’s product label, citing that the benefits of the one-dose shot outweigh its risks.
J&J Chief Scientific Officer Paul Stoffels said: “It’s an extremely rare event. We hope by making people aware as well as putting clear diagnostic and therapeutic guidance in place that we can restore the confidence in our vaccine.”
J&J said it would fulfill its commitments to ship 200 million doses in Europe and 100 million in the United States.
Market implications
The J&J’s positive news failed to have any impact on the market sentiment in the US last session, as surging covid cases worldwide overshadow.
At the time of writing, the S&P 500 futures trade 0.08% lower at 4,125 while the US dollar holds onto the recovery gains above 91.00.
Author
Dhwani Mehta
FXStreet
Residing in Mumbai (India), Dhwani is a Senior Analyst and Manager of the Asian session at FXStreet. She has over 10 years of experience in analyzing and covering the global financial markets, with specialization in Forex and commodities markets.
